|
gptkbp:instance_of
|
gptkb:skincare_product
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Lidocaine
|
|
gptkbp:application
|
gptkb:skincare_product
|
|
gptkbp:brand
|
gptkb:Lidoderm
|
|
gptkbp:class
|
gptkb:hospital
|
|
gptkbp:clinical_trial
|
Phase III
chronic pain management
Lidoderm vs placebo
effective for pain reduction
|
|
gptkbp:contraindication
|
severe liver disease
severe heart block
hypersensitivity to lidocaine
|
|
gptkbp:dosage_form
|
gptkb:spacecraft
|
|
gptkbp:duration
|
up to 12 hours
12 hours on, 12 hours off
|
|
gptkbp:education
|
apply to clean, dry skin
|
|
gptkbp:effective_date
|
2007-05-17
|
|
gptkbp:exemplifies
|
gptkb:Company
non-woven fabric
polyisobutylene
silicone adhesive
|
|
gptkbp:feedback
|
high
|
|
gptkbp:formulation
|
matrix-type patch
|
|
gptkbp:frequency
|
up to 3 patches at once
|
|
gptkbp:has_ability
|
5% lidocaine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lidoderm
|
|
gptkbp:indication
|
postherpetic neuralgia
|
|
gptkbp:ingredients
|
gptkb:lidocaine
|
|
gptkbp:interacts_with
|
CY P3 A4 inhibitors
|
|
gptkbp:is_used_for
|
pain relief
|
|
gptkbp:lifespan
|
1.5 hours
|
|
gptkbp:manager
|
topical
transdermal
|
|
gptkbp:manufacturer
|
gptkb:Endo_Pharmaceuticals
|
|
gptkbp:market
|
ongoing
prescription only
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
single-use patches
|
|
gptkbp:pharmacokinetics
|
widely available
minimal systemic absorption
|
|
gptkbp:population
|
adults
|
|
gptkbp:previous_name
|
lidocaine patch
|
|
gptkbp:price
|
varies by pharmacy
|
|
gptkbp:provides_information_on
|
recommended for neuropathic pain
|
|
gptkbp:regulatory_compliance
|
FDA approved
|
|
gptkbp:requires
|
available online
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
dizziness
nausea
skin irritation
edema
pruritus
local anesthetic effect
local erythema
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
high
|